• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病作为慢性肾脏病的一个驱动因素。

NAFLD as a driver of chronic kidney disease.

作者信息

Byrne Christopher D, Targher Giovanni

机构信息

Nutrition and Metabolism, Faculty of Medicine, University of Southampton, Southampton, UK; Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton, UK.

Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.

出版信息

J Hepatol. 2020 Apr;72(4):785-801. doi: 10.1016/j.jhep.2020.01.013. Epub 2020 Feb 12.

DOI:10.1016/j.jhep.2020.01.013
PMID:32059982
Abstract

Non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) are worldwide public health problems, affecting up to 25-30% (NAFLD), and up to 10-15% (CKD) of the general population. Recently, it has also been established that there is a strong association between NAFLD and CKD, regardless of the presence of potential confounding diseases such as obesity, hypertension and type 2 diabetes. Since NAFLD and CKD are both common diseases that often occur alongside other metabolic conditions, such as type 2 diabetes or metabolic syndrome, elucidating the relative impact of NAFLD on the risk of incident CKD presents a substantial challenge for investigators working in this research field. A growing body of epidemiological evidence suggests that NAFLD is an independent risk factor for CKD and recent evidence also suggests that associated factors such as metabolic syndrome, dysbiosis, unhealthy diets, platelet activation and processes associated with ageing could also contribute mechanisms linking NAFLD and CKD. This narrative review provides an overview of the literature on: a) the evidence for an association and causal link between NAFLD and CKD and b) the underlying mechanisms by which NAFLD (and factors strongly linked with NAFLD) may increase the risk of developing CKD.

摘要

非酒精性脂肪性肝病(NAFLD)和慢性肾脏病(CKD)是全球性的公共卫生问题,分别影响高达25%-30%(NAFLD)和10%-15%(CKD)的普通人群。最近还证实,无论是否存在肥胖、高血压和2型糖尿病等潜在混杂疾病,NAFLD与CKD之间都存在密切关联。由于NAFLD和CKD都是常见疾病,常与2型糖尿病或代谢综合征等其他代谢状况同时出现,因此阐明NAFLD对CKD发病风险的相对影响,对该研究领域的研究人员来说是一项重大挑战。越来越多的流行病学证据表明,NAFLD是CKD的独立危险因素,最近的证据还表明,代谢综合征、肠道菌群失调、不健康饮食、血小板活化以及与衰老相关的过程等相关因素,也可能是NAFLD与CKD之间联系的潜在机制。本叙述性综述概述了以下方面的文献:a)NAFLD与CKD之间存在关联和因果关系的证据;b)NAFLD(以及与NAFLD密切相关的因素)可能增加CKD发病风险的潜在机制。

相似文献

1
NAFLD as a driver of chronic kidney disease.非酒精性脂肪性肝病作为慢性肾脏病的一个驱动因素。
J Hepatol. 2020 Apr;72(4):785-801. doi: 10.1016/j.jhep.2020.01.013. Epub 2020 Feb 12.
2
A brief review on the rising incidence of chronic kidney diseases and non-alcoholic fatty liver disease.慢性肾脏病和非酒精性脂肪性肝病发病率上升的简要综述。
Physiol Int. 2019 Dec 1;106(4):305-310.
3
MAFLD and CKD: An Updated Narrative Review.MAFLD 和 CKD:更新的叙述性综述。
Int J Mol Sci. 2022 Jun 23;23(13):7007. doi: 10.3390/ijms23137007.
4
Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes.非酒精性脂肪性肝病,糖尿病前期和糖尿病患者心血管疾病事件和基于 eGFR 的慢性肾脏病的代谢目标达标。
Metabolism. 2021 Nov;124:154874. doi: 10.1016/j.metabol.2021.154874. Epub 2021 Sep 10.
5
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.非酒精性脂肪性肝病、胰岛素抵抗、代谢综合征及其与血管风险的关系。
Metabolism. 2021 Jun;119:154770. doi: 10.1016/j.metabol.2021.154770. Epub 2021 Apr 14.
6
The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease.非酒精性脂肪性肝病与肾脏疾病之间的相互作用
Clin Liver Dis. 2022 May;26(2):213-227. doi: 10.1016/j.cld.2022.01.008. Epub 2022 Apr 1.
7
Nonalcoholic fatty liver disease - A multisystem disease?非酒精性脂肪性肝病——一种多系统疾病?
World J Gastroenterol. 2016 Nov 21;22(43):9488-9505. doi: 10.3748/wjg.v22.i43.9488.
8
Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease.非酒精性脂肪性肝病与慢性肾脏病的临床转归。
Nephrol Dial Transplant. 2019 Mar 1;34(3):449-457. doi: 10.1093/ndt/gfx381.
9
[Non-alcoholic fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases].[非酒精性脂肪性肝病作为代谢综合征的一个组成部分及其与其他肝外疾病的因果关系]
Orv Hetil. 2017 Dec;158(52):2051-2061. doi: 10.1556/650.2017.30936.
10
Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease.非酒精性脂肪性肝病增加了发生慢性肾脏病的风险。
United European Gastroenterol J. 2020 Oct;8(8):942-948. doi: 10.1177/2050640620944098. Epub 2020 Jul 23.

引用本文的文献

1
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.代谢功能障碍相关脂肪性肝病(MASLD):肠道微生物群、胰岛素抵抗和糖尿病之间的相互作用
Front Med (Lausanne). 2025 Aug 14;12:1618275. doi: 10.3389/fmed.2025.1618275. eCollection 2025.
2
Analysis of gastric electrical rhythm in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus.代谢功能障碍相关脂肪性肝病和2型糖尿病患者胃电节律分析
World J Hepatol. 2025 Jul 27;17(7):109067. doi: 10.4254/wjh.v17.i7.109067.
3
Hepato-Renal Crosstalk in Acute and Chronic Disease: From Shared Pathways to Therapeutic Targets.
急慢性疾病中的肝肾相互作用:从共同通路到治疗靶点
Biomedicines. 2025 Jul 1;13(7):1618. doi: 10.3390/biomedicines13071618.
4
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs.老年人脂肪性肝病:临床意义与未满足的需求
Nutrients. 2025 Jun 30;17(13):2189. doi: 10.3390/nu17132189.
5
Nonlinear relationship between body fat percentage and NAFLD mediated by METS-IR: threshold effects and subgroup differences.由代谢综合征胰岛素抵抗(METS-IR)介导的体脂百分比与非酒精性脂肪性肝病(NAFLD)之间的非线性关系:阈值效应和亚组差异。
Sci Rep. 2025 Jul 10;15(1):24917. doi: 10.1038/s41598-025-10765-w.
6
Integrated Patient Digital and Biomimetic Twins for Precision Medicine: A Perspective.用于精准医学的综合患者数字双胞胎和仿生双胞胎:一种观点
Semin Liver Dis. 2025 Jul 23. doi: 10.1055/a-2649-1560.
7
Serum insulin-like growth factor binding protein 2 is associated with hepatic steatosis in adults with metabolic dysfunction-associated steatotic liver disease.血清胰岛素样生长因子结合蛋白2与代谢功能障碍相关脂肪性肝病成人患者的肝脂肪变性有关。
Endocr Connect. 2025 Jul 17;14(7). doi: 10.1530/EC-25-0285. Print 2025 Jul 1.
8
Obesity drives the link between liver fat and depression: Cross-sectional and prospective investigations.肥胖导致肝脏脂肪与抑郁之间的关联:横断面研究与前瞻性研究
Diabetes Obes Metab. 2025 Sep;27(9):5127-5134. doi: 10.1111/dom.16562. Epub 2025 Jun 24.
9
The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease: comment.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病和代谢相关脂肪性肝病患者通过磁共振成像-质子密度脂肪分数检测的肝脂肪变性的影响:评论
Intern Emerg Med. 2025 Jun 17. doi: 10.1007/s11739-025-04024-z.
10
CARDIAL-MS (CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome): a new proposition for an integrated multisystem metabolic disease.心脏-肾脏-糖尿病-肝脏-代谢综合征(CARDIAL-MS):一种综合多系统代谢疾病的新定义。
Diabetol Metab Syndr. 2025 Jun 16;17(1):218. doi: 10.1186/s13098-025-01796-4.